APPROXIMATELY TEN TO FIFTEEN PERCENT OF WOMEN WITH BREAST CANCER HAVE AN AGGRESSIVE AND DIFFICULT-TO-TREAT TYPE CALLED TRIPLE NEGATIVE BREAST CANCER.
“FROM A TREATMENT STANDPOINT, THEY ARE MORE CHALLENGING IN THATWE DON’T HAVE SPECIFIC, TARGETED THERAPIES FOR TRIPLE
NEGATIVE BREAST CANCER, AT LEAST NOT YET.” BUT THERE
IS HOPE. AN ANNUAL EVENT CALLED THE TRIPLE NEGATIVE BREAST CANCER SYMPOSIUM ACCELERATES RESEARCH AND CHANGES THE TREATMENT OUTLOOK FOR THESE WOMEN.

“WE HAVE PEOPLE FROM EUROPE AND PEOPLE FROM THE US, WE HAVE LAB SCIENTISTS, WE HAVE CLINICIANS, AND ALL THESE INDIVIDUALS ARE HERE TO SPEND A DAY TALKING ABOUT TRIPLE NEGATIVE BREAST CANCER AND WHERE THE FIELD NEEDS TO GO.” (END SOUND BITE) THIS YEAR, ATTENDEES DESCRIBED RESEARCH THEYʼRE DOING TO FIND MORE EFFECTIVE TREATMENTS AND DETERMINE WHY SOME TUMORS ARE
RESISTANT TO STANDARD BREAST CANCER DRUGS.

THE TRIPLE NEGATIVE BREAST CANCER FOUNDATION, SUSAN G. KOMEN FOR THE CURE AND THE BREAST CANCER RESEARCH FOUNDATION ARE SYMPOSIUM SPONSORS. LEARN MORE AT TNBCFOUNDATION.ORG.

source